To profile the circulating miRNAs differentially modulated by drug treatment, we screened 2578 miRNAs using TaqMan microRNA arrays in plasma samples from five HC and five HF patients (NYHA class II-III) at baseline and follow-up, selected from the global population based on the observed reduction in NT-proBNP and proSP-B (−75.1% ± 19.6% and −26.6% ± 10.1% reduction after treatment, respectively). This evidence concerns the gene NPPB and hydrops fetalis.